Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
Rhythm Pharmaceuticals (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focusing on rare neuroendocrine diseases, has announced two upcoming events. First, the company will host a conference call and webcast on August 6, 2024, at 8:00 a.m. ET to report its second quarter 2024 financial results and provide a corporate update. Participants can register for the call online.
Additionally, David Meeker, M.D., Chair, President and CEO of Rhythm, will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference in Boston on August 13, 2024, at 11:00 a.m. ET. Both events will be webcast live and archived on the company's website for 30 days following the presentations.
Rhythm Pharmaceuticals (Nasdaq: RYTM), un'azienda biofarmaceutica in fase commerciale che si concentra su malattie neuroendocrine rare, ha annunciato due eventi imminenti. Primo, l'azienda ospiterà una conference call e un webcast il 6 agosto 2024, alle 8:00 ora dell'Est per riportare i suoi risultati finanziari del secondo trimestre 2024 e fornire un aggiornamento aziendale. I partecipanti possono registrarsi per la chiamata online.
Inoltre, David Meeker, M.D., Presidente e CEO di Rhythm, parteciperà a una chiacchierata informale alla 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity a Boston il 13 agosto 2024, alle 11:00 ora dell'Est. Entrambi gli eventi saranno trasmessi in diretta e archiviati sul sito web dell'azienda per 30 giorni dopo le presentazioni.
Rhythm Pharmaceuticals (Nasdaq: RYTM), una compañía biofarmacéutica en etapa comercial que se centra en enfermedades neuroendocrinas raras, ha anunciado dos eventos próximos. Primero, la empresa organizará una conferencia telefónica y un webcast el 6 de agosto de 2024, a las 8:00 a.m. ET para informar sobre sus resultados financieros del segundo trimestre de 2024 y proporcionar una actualización corporativa. Los participantes pueden registrarse para la llamada en línea.
Además, David Meeker, M.D., Presidente y CEO de Rhythm, participará en una charla informal en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity en Boston el 13 de agosto de 2024, a las 11:00 a.m. ET. Ambos eventos se transmitirán en vivo y se archivarían en el sitio web de la empresa durante 30 días después de las presentaciones.
리듬 제약 (Nasdaq: RYTM)은 희귀 신경내분비 질환에 초점을 맞춘 상업 단계의 바이오 제약 회사로 두 가지 다가오는 이벤트를 발표했습니다. 첫째, 회사는 2024년 8월 6일 오전 8시 (동부 표준시)에 2024년 2분기 재무 결과를 보고하고 기업 업데이트를 제공하기 위해 회의 전화 및 웹캐스트를 개최합니다. 참가자는 온라인으로 전화를 등록할 수 있습니다.
추가로, David Meeker, M.D., 리듬의 회장, 사장 및 CEO는 Canaccord Genuity 제44회 연례 성장 컨퍼런스에 참여하여 2024년 8월 13일 오전 11시 (동부 표준시)에 열린 대화에 참석합니다. 두 이벤트 모두 실시간으로 웹캐스트되며 발표 후 30일 동안 회사 웹사이트에 보관됩니다.
Rhythm Pharmaceuticals (Nasdaq: RYTM), une entreprise biopharmaceutique en phase commerciale se concentrant sur les maladies neuroendocrines rares, a annoncé deux événements à venir. Premièrement, l'entreprise organisera une conférence téléphonique et un webinaire le 6 août 2024 à 8h00 ET pour présenter ses résultats financiers du deuxième trimestre 2024 et fournir une mise à jour de l'entreprise. Les participants peuvent s'inscrire en ligne pour l'appel.
De plus, David Meeker, M.D., Président et CEO de Rhythm, participera à une discussion informelle lors de la 44e Conférence Annuelle sur la Croissance de Canaccord Genuity à Boston le 13 août 2024 à 11h00 ET. Les deux événements seront diffusés en direct et archivés sur le site web de l'entreprise pendant 30 jours suivant les présentations.
Rhythm Pharmaceuticals (Nasdaq: RYTM), ein biopharmazeutisches Unternehmen in der Handelsphase, das sich auf seltene neuroendokrine Erkrankungen konzentriert, hat zwei bevorstehende Veranstaltungen angekündigt. Zuerst wird das Unternehmen am 6. August 2024 um 8:00 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um seine Finanzergebnisse für das zweite Quartal 2024 bekannt zu geben und ein Unternehmensupdate zu geben. Teilnehmer können sich online für die Konferenzregistrierung anmelden.
Darüber hinaus wird David Meeker, M.D., Vorsitzender, Präsident und CEO von Rhythm, an einem Fireside-Chat auf der 44. Jahreskonferenz für Wachstum von Canaccord Genuity in Boston am 13. August 2024 um 11:00 Uhr ET teilnehmen. Beide Veranstaltungen werden live über das Internet übertragen und für 30 Tage nach den Präsentationen auf der Unternehmenswebsite archiviert.
- None.
- None.
BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 6, 2024 to report its second quarter 2024 financial results and provide a corporate update.
To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start.
Also today, Rhythm announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Canaccord Genuity 44th Annual Growth Conference in Boston, MA on Tuesday, August 13, 2024, at 11:00 a.m. ET.
Live webcasts of both the financial results conference call and the fireside chat will be available under "Events and Presentations" in the Investor Relations section of the Rhythm Pharmaceuticals website at http://ir.rhythmtx.com/. The archived webcast of the financial results conference call will be available on Rhythm’s website approximately two hours after it concludes and will be available for 30 days following the call. A replay of the Canaccord Genuity webcast will also be available on the Rhythm website for 30 days following the presentation.
About Rhythm Pharmaceuticals
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing, or patients with a clinical diagnosis of Bardet-Biedl syndrome (BBS). Both the European Commission (EC) and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists LB54640 and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.
Setmelanotide Indication
In the United States, setmelanotide is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to POMC, PCSK1 or LEPR deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1 or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) or BBS.
In the European Union, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. In Europe, setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.
Limitations of Use
Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:
- Obesity due to suspected POMC, PCSK1 or LEPR deficiency with POMC, PCSK1 or LEPR variants classified as benign or likely benign
- Other types of obesity not related to POMC, PCSK1 or LEPR deficiency, or BBS, including obesity associated with other genetic syndromes and general (polygenic) obesity.
Contraindication
Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.
WARNINGS AND PRECAUTIONS
Skin Pigmentation and Darkening of Pre-Existing Nevi: Generalized increased skin pigmentation and darkening of pre-existing nevi have occurred because of its pharmacologic effect. Full body skin examinations prior to initiation and periodically during treatment should be conducted to monitor pre-existing and new pigmentary lesions.
Heart rate and blood pressure monitoring: In Europe, heart rate and blood pressure should be monitored as part of standard clinical practice at each medical visit (at least every 6 months) for patients treated with setmelanotide.
Disturbance in Sexual Arousal: Spontaneous penile erections in males and sexual adverse reactions in females have occurred. Patients who have an erection lasting longer than 4 hours should seek emergency medical attention.
Depression and Suicidal Ideation: Depression and suicidal ideation have occurred. Patients should be monitored for new onset or worsening depression or suicidal thoughts or behaviors. Consideration should be given to discontinuing setmelanotide if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.
Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue setmelanotide.
Pediatric Population: The prescribing physician should periodically assess response to setmelanotide therapy. In growing children, the impact of weight loss on growth and maturation should be evaluated. In Europe, the prescribing physician should monitor growth (height and weight) using age- and sex-appropriate growth curves.
Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants: Setmelanotide is not approved for use in neonates or infants. Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and low birth weight infants treated with benzyl alcohol-preserved drugs.
ADVERSE REACTIONS
Most common adverse reactions (incidence ≥
USE IN SPECIFIC POPULATIONS
Lactation: Not recommended when breastfeeding.
To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See section 4.8 of the Summary of Product Characteristics for information on reporting suspected adverse reactions in Europe.
Please see the full Prescribing Information for additional Important Safety Information.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the release of our financial results and our participation in upcoming events and presentations, and the date, time, and content thereof. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including, but not limited to, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, our ability to successfully commercialize setmelanotide, our liquidity and expenses, our ability to retain our key employees and consultants, and to attract, retain and motivate qualified personnel, and general economic conditions, and the other important factors discussed under the caption “Risk Factors” in Quarterly Report on Form 10-Q for the three months ended March 31, 2024 and our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.
Corporate Contact:
David Connolly
Head of Investor Relations and Corporate Communications
Rhythm Pharmaceuticals, Inc.
857-264-4280
dconnolly@rhythmtx.com
Media Contact:
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com
![](https://ml.globenewswire.com/media/ZTY3YmVlN2ItZTUxMS00YjQ0LWE0ZGYtMTQ0Nzk0NzZlZTRmLTEwMjI3Nzc=/tiny/Rhythm-Pharmaceuticals-Inc-.png)
FAQ
When will Rhythm Pharmaceuticals (RYTM) report its Q2 2024 financial results?
Where can I access the webcast of Rhythm Pharmaceuticals' (RYTM) Q2 2024 financial results?
Will Rhythm Pharmaceuticals (RYTM) participate in any investor conferences in August 2024?